There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
How many lines of endocrine therapy do patients receive before chemotherapy?
Rowan Chlebowski, MD
Professor and Chief
Harbor-UCLA Medical Center
Are there multiple molecules that regulate cell proliferation?
Adam Brufsky, MD
Professor of Medicine
University of Pittsburgh School of Medicine
Can changing the MOA within the endocrine therapy class overcome treatment resistance?
Virginia Kaklamani, MD
University of Texas Health Science Center
San Antonio, Texas
What is the efficacy of subsequent endocrine monotherapy following progression on initial treatment?
Stephen Jones, MD
Founding Partner of Texas Oncology
What are the driving factors of endocrine resistance?
Michael Naughton, MD
Assistant Professor of Medicine
University of Washington
St. Louis, Missouri
aBC, advanced breast cancer; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; MOA, mechanism of action.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Laboratory Tests and Monitoring
Please see full Prescribing Information.